Table 2 All reported and/or observed adverse events in the 15 patients treated with leflunomide, indicated per individual patient.

	Patients
Adverse event	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	Total n (%)
Diarrhoea	+		+			+	+			+	+				+	7 (47)
GI discomfort	+	+							+	+	+			+		6 (40)
Anorexia								+							+	2 (13)
Oral ulcers		+			+											2 (13)
Hair loss	+	+			+	+		+				+		+		7 (47)
Headache		+				+			+		+			+		5 (33)
Fatigue/lethargy		+							+				+			3 (20)
Dysaesthesia		+									+					2 (13)
Dizziness			+						+			+			+	4 (26)
Alcohol intolerance			+													1 (6)
Weight loss >2 kg				+		+	+					+			+	5 (33)
Dyspnoea						+										1 (6)
↑Transpiration							+									1 (6)
↑Conjunctivitis											+		+			2 (13)
Pharyngitis											+			+		2 (13)
↓Libido											+					1 (6)
Mood changes											+					1 (6)
↓Taste												+				1 (6)
ALAT 1–2* ULN										+		+				2 (13)
ALAT >2* ULN	+*							+†								2 (13)
↑Pre‐existing ↑RR	+									+						2 (13)
LE skin lesions			+‡§			+¶**		+1,2	+1,2			+ 1				5 (33)
Other skin lesions					+		+††			+‡‡			+			3 (20)
Leucopenia 3–4×109/l			+	+		+			+							4 (26)
Leucopenia <3×109/l								+					+			2 (13)
Anaemia <7.4 mmol/l			+	+	+	+							+			5 (33)

ALAT, alanine aminotransferase; GI, gastrointestinal; LE, lupus erythematosus; ULN, upper limit of normal; ↑RR, hypertension; ↓, decrease; +, present.

*Requiring temporary stop of leflunomide (LEF) treatment. After normalisation of ALAT, LEF was restarted at a dose of 10 mg OD.

†Requiring temporary stop of LEF treatment twice. After first normalisation of ALAT, LEF was restarted at a dose of 10 mg. After second normalisation, LEF 10 mg OD was restarted without subsequent increase of ALAT again.

‡Causing permanent withdrawal at 17 weeks.

§Biopsy proven.

¶Not biopsy proven.

**Reactivation of lesions that had been occurring before LEF treatment.

††Itching maculopapular rash.

‡‡Oral lesions, self‐reported, not confirmed.